Ambrose Kristen 4

What Happened
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals (VRTX), disposed of a total of 769 shares in late February 2026 for aggregate proceeds of $373,326. The filing shows a 546-share disposition on 2026-02-24 at $485.11 per share ($264,870) listed as an F transaction (payment of exercise price or tax liability), and a 223-share open-market sale on 2026-02-25 at $486.35 per share ($108,456). Both transactions are disposals (sales), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-24 — 546 shares @ $485.11 (F: payment of exercise price/tax liability) — $264,870
  • 2026-02-25 — 223 shares @ $486.35 (S: open-market sale) — $108,456
• Total sold: 769 shares for $373,326
• Shares owned after transaction: Not provided in the supplied filing excerpt
• Footnote: Filing states the transaction(s) were made pursuant to Ms. Ambrose’s company-approved Rule 10b5-1 trading plan entered 08/08/2025
• Filing/timeliness: Report filed 2026-02-26 for transactions reported 2026-02-24 — appears to be timely (filed within the normal Form 4 reporting window)

Context

• The "F" code typically indicates shares were surrendered to satisfy tax withholding or exercise-price obligations following an option exercise; the separate "S" transaction is a standard open-market sale.
• Trades executed under a 10b5-1 plan are pre-arranged and do not necessarily reflect the insider’s current view of the company.
• These are routine insider dispositions; no purchase or new award was reported in this filing.